Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178465 | 1.00 | SIRT1 (0.48) | SIRT1BAZ2BMAPTNR1H2NR1H3 | |
| SCHEMBL15107560 | 1.00 | SIRT1 (0.48) | SIRT1BAZ2BMAPTNR1H2NR1H3 | |
| SCHEMBL1178463 | 1.00 | SIRT1 (0.48) | SIRT1BAZ2BMAPTNR1H2NR1H3 | |
| SCHEMBL12637107 | 0.90 | HTR1A (0.51) | SIRT1BAZ2BMAPTHTR1AHTR1D | |
| SCHEMBL1758752 | 0.87 | SIRT1 (0.49) | SIRT1BAZ2BMAPTNR1H2NR1H3 | |
| SCHEMBL13626289 | 0.87 | RB1 (0.47) | SIRT1BAZ2BHTR1AHTR1DHTR1B | |
| SCHEMBL1781342 | 0.87 | SIRT1 (0.49) | SIRT1BAZ2BMAPTNR1H2NR1H3 | |
| SCHEMBL12647415 | 0.86 | HTR1A (0.43) | BAZ2BNR1H2NR1H3HTR1AHTR1D | |
| SCHEMBL2022179 | 0.84 | KMT2A (0.40) | NR1H2NR1H3HTR1AHTR1DHTR1B | |
| SCHEMBL2022176 | 0.84 | KMT2A (0.40) | NR1H2NR1H3HTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2297100-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2297100-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8183388-B2 | Androgen receptor modulator and uses thereof | ELI LILLY AND COMPANY (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183388-B2 | Androgen receptor modulator and uses thereof | ELI LILLY AND COMPANY (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110118326-A1 | Androgen Receptor Modulator and Uses Thereof | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118326-A1 | Androgen Receptor Modulator and Uses Thereof | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011060019-A1 | ANDROGEN RECEPTOR MODULATOR AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-2297100-A1 | TETRAHYDROCYCLOPENTAÝB¨INDOLE ANDROGEN RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009140448-A1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118326-A1 | Androgen Receptor Modulator and Uses Thereof | AR, SHBG, ESRRA | SIRT1 676/4885BAZ2B 3795/4885MAPT 3554/4885 |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | AR, ADRA1B, ADRB1 | SIRT1 1020/4885BAZ2B 3793/4885MAPT 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.